Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-10
2006-01-10
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S235000, C548S236000
Reexamination Certificate
active
06984653
ABSTRACT:
This invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by the formula:wherein m is an integer of 1 to 3; n is an integer of 1 or 2; R1is a halogen atom or an optionally halogenated C1-2alkyl group; each of R2and R3is, same or different, a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R4is a group represented by the formula:wherein p is an integer of 2 to 5; R5is a C1-4alkyl group substituted by alkoxycarbonyl group, carbamoyl group, carbamoyloxy group, alkylsulfonyl group, alkylsulfinyl group, sulfamoyl group, carbamoylamino group, alkylsulfonylamino group, acylamino group, and the like; or a salt thereof and a pharmaceutical composition comprising thereof.
REFERENCES:
patent: 5656655 (1997-08-01), Spada et al.
patent: 6211215 (2001-04-01), Momose et al.
patent: 6716863 (2004-04-01), Tasaka et al.
patent: 6743924 (2004-06-01), Ikemoto et al.
patent: 2002/0173526 (2002-11-01), Tasaka et al.
patent: 2003/0069419 (2003-04-01), Ikemoto et al.
patent: 2004/0024035 (2004-02-01), Tasaka et al.
patent: 2004/0053972 (2004-03-01), Nara
patent: 2004/0058956 (2004-03-01), Akiyama et al.
patent: 2004/0116330 (2004-06-01), Naito et al.
patent: 2004/0138160 (2004-07-01), Naito et al.
patent: 1350792 (2003-10-01), None
patent: 1350793 (2003-10-01), None
patent: WO 9803505 (1998-01-01), None
patent: WO 200248141 (2002-06-01), None
patent: WO 2003059907 (2003-07-01), None
Ross, J., et al., “Targeted Therapy in Breast Cancer: the HER-2
eu Gene and Protein,” Molecular & Cellular Proteomics, vol. 3(4), pp. 379-398 (Apr. 2004), at p. 381, col. 2, lines 12-38.
Ducreux, M., et al., “Emerging drugs in pancreatic cancer,” Expert Opin. Emerg. Drugs, vol. 9(1), pp. 73-89 (May 2004), at p. 79, col. 1, line 19 et seq.
Barton, J., et al., “Growth factors and their receptors: new targets for prostrate cancer therapy,” Urology, vol. 58, Suppl. 2A, pp. 114-112 (Aug. 2001), at p. 118, col. 2, line 6, et seq.
Sawyers, C., “Rational therapeutic intervention in cancer: kinases as drug targets,” Current Opinion in Genetics & Development, vol. 12(1), pp. 111-115 (Feb. 2002), at p. 111, lines 29-48; p. 113, lines 38-40; and p. 111, line 47 to p. 112, line 4.
U.S. Food and Drug Administration, “FDA Statement on Iressa,” released Dec. 17, 2004, p. 1, lines 8-9.
“Avastin-Tarceva Combo Provides ‘One-Two’ Punch Against Lung Cancer,” Science Daily (Jun. 7, 2004).
Goldman, B., “For Investigational Targeted Drugs, Combination Trials pose Challenges,” J. National Cancer Institute, vol. 95(23), pp. 1744-1746 (Dec. 3, 2003) at p. 1744, 1st col., lines 40-53.
Robinson, D., et al., “The protein tyrosine kinase family of the human enome,” Oncogene, vol. 19(49), pp. 5548-5557 (Nov. 2000), at Abstract; at p. 5548, col. 2, lines 42-50; at p. 5549, Table 1; and at p. 5550, Table 2b.
Awada, A., et al., “The pipeline of new anticancer agents for breast cancer treatment in 2003,” Critical Reviews in Oncology/Hematology, vol. 48(1), pp. 45-63 (Oct. 2003), at p. 46, col. 2, line 3.
Nahta, R., et al., “Novel pharmacological approaches in the treatment of breast cancer,” Expert Opin. Investigational Drugs, vol. 12(6), pp. 909-921 (Jun. 2003), at p. 913, col. 1, line 51 to p. 914, col. 2, line 14 (“Tyrosine kinase inhibitors”).
Nahta, R., et al., “Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention,” The Oncologist, vol. 8(1), pp. 5-17 (Feb. 2003), at p. 8, ;line 19 et seq.
Bartlett, J., et al., “The clinical evaluation of HER-2 status: which test to use?” J. Pathology, vol. 199(4), pp. 411-417 (Apr. 2003), at p. 412, col. 1, lines 4-18; also p. 412, lines 24-26; also at p. 411, col. 1, line 1 and col. 2, lines 1-5.
J.S. Ross, et al., “The HER-2
eu Gene and Protein in Breast Cancer 2003: Biomaker and Target of Therapy”, The Oncologist, (Aug. 2003), pp. 307-325, vol. 8.
Naito Ken-ichiro
Tasaka Akihiro
Chao Mark
McKane Joseph K.
Paviglianiti Anthony J.
Ramesh Elaine M.
Takeda Pharmaceutical Company Limited
LandOfFree
Heterocyclic compounds, oxazole derivatives, process for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, oxazole derivatives, process for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds, oxazole derivatives, process for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553815